Predictive markers of immune response in glioblastoma: hopes and facts.
Future Oncol
; 16(15): 1053-1063, 2020 May.
Article
em En
| MEDLINE
| ID: mdl-32270715
ABSTRACT
Immune-checkpoint inhibitors (ICI) represent a concrete hope for patients with advanced solid tumors. Indeed, patients responding to these agents may experience a long-lasting response. Recently, results of interventional clinical trials investigated the role of ICIs in patients with glioblastoma. Results of these studies suggested that only a small percentage of these patients could benefit from these agents. Research of predictive markers assumes a critical importance to adequately select patients likely to benefit from ICIs. Molecular and clinical variables associated to tumors and patients have been evaluated as potential predictive markers. Main aim of the current work is to summarize and critically evaluate current knowledge in this field.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Glioblastoma
/
Inibidores de Checkpoint Imunológico
/
Imunidade
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article